{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:31:50Z","timestamp":1792693910407,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives. Pulmonary aspergillosis is a severe respiratory infection caused by Aspergillus spp., whose resistance profiles and invasive attitude complicate therapeutical strategies. Several aspergillosis cases emerged as superinfections during the SARS-CoV-2 pandemic when isavuconazole and amphotericin B became essential antifungal alternatives. The main purpose of the present study was to investigate a possible synergic activity between these molecules against Aspergillus spp. isolated from respiratory samples. Methods. The gradient test method detected isavuconazole and amphotericin B MIC values, prompting an arrangement of their combination into an R.P.M.I. agar medium. According to Liofilchem s.r.l. instructions, the FIC index was used to establish synergy, additivity, indifference, or antagonism. Results. Among 36 Aspergillus spp. isolates, only A. fumigatus strains showed both synergy and additivity episodes. A. niger reported the highest antagonism percentage, while A. terreus revealed several indifference episodes. Conclusions. Isavuconazole and amphotericin B remain fundamental therapeutical alternatives, including a possible synergic effect against A. fumigatus. On the basis of this species-related difference, further studies will be essential to investigate different antifungal drug combinations against filamentous fungi isolates.<\/jats:p>","DOI":"10.3390\/antibiotics13111005","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:50:08Z","timestamp":1729853408000},"page":"1005","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0256-956X","authenticated-orcid":false,"given":"Maddalena","family":"Calvo","sequence":"first","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0634-2874","authenticated-orcid":false,"given":"Flavio","family":"Lauricella","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maurizia","family":"Mellini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Scalia","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-8545","authenticated-orcid":false,"given":"Laura","family":"Trovato","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.diii.2015.01.005","article-title":"Pulmonary aspergillosis","volume":"96","author":"Chabi","year":"2015","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.amjmed.2020.02.025","article-title":"Pulmonary Aspergillosis: What the Generalist Needs to Know","volume":"133","author":"Gao","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"220114","DOI":"10.1183\/16000617.0114-2022","article-title":"Pulmonary aspergillosis: Diagnosis and treatment","volume":"31","author":"Lamoth","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","unstructured":"McKeny, P.T., Nessel, T.A., and Zito, P.M. (2023, September 05). Antifungal Antibiotics. [Updated 7 March 2023], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538168\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Arastehfar, A., Carvalho, A., van de Veerdonk, F.L., Jenks, J.D., Koehler, P., Krause, R., Cornely, O.A., SPerlin, D., Lass-Fl\u00f6rl, C., and Hoenigl, M. (2020). COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J. Fungi, 6.","DOI":"10.3390\/jof6020091"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ullah, N., Sepulcri, C., and Mikulska, M. (2022). Isavuconazole for COVID-19-Associated Invasive Mold Infections. J. Fungi, 8.","DOI":"10.3390\/jof8070674"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Teng, Q., Ye, X., Wang, B., Zhang, X., Tao, Z., Yin, X., and Yang, Q. (2024). Case report: Successful combination therapy with isavuconazole and amphotericin B in treatment of disseminated Candida tropicalis infection. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1397539"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Calvo, M., Scalia, G., Palermo, C.I., Oliveri, S., and Trovato, L. (2023). Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020251"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/mmy\/myy071","article-title":"Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species","volume":"57","author":"Trovato","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ortalli, G., Oliva, E., Lo Cascio, G., on behalf of the Medical Mycology Committee (CoSM)\u2014Italian Association of Clinical Microbiologists (AMCLI), and Farina, C. (2023). In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales. Pathogens, 12.","DOI":"10.3390\/pathogens12070948"},{"key":"ref_14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2023, September 20). Breakpoint Tables for Interpretation of MICs for Antifungal Agents, Version 10.0. Available online: http:\/\/www.eucast.org\/astoffungi\/clinicalbreakpointsforantifungals\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"Gebremariam","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","first-page":"101367","article-title":"Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient","volume":"32","author":"Trovato","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/08850666211047166","article-title":"Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting","volume":"37","author":"Hashim","year":"2022","journal-title":"J. Intensive Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3201\/eid2704.204895","article-title":"COVID-19-Associated Pulmonary Aspergillosis, March-August 2020","volume":"27","author":"Sprute","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jmii.2020.09.004","article-title":"COVID-19 associated with pulmonary aspergillosis: A literature review","volume":"54","author":"Lai","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/ccr3.4051","article-title":"Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillusterreus: A case study","volume":"9","author":"Abolghasemi","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sk\u00f3ra, M., Gajda, M., Namys\u0142, M., Wordliczek, J., Zorska, J., Piekie\u0142ko, P., \u017b\u00f3\u0142towska, B., Krzy\u015bciak, P., Heczko, P.B., and W\u00f3jkowska-Mach, J. (2023). COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit Patients from Poland. J. Fungi, 9.","DOI":"10.3390\/jof9060666"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Trovato, L., Scalia, G., Domina, M., and Oliveri, S. (2018). Environmental Isolates of Multi-Azole-Resistant Aspergillus spp. in Southern Italy. J. Fungi, 4.","DOI":"10.3390\/jof4040131"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1128\/AAC.48.12.4922-4925.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2172264","DOI":"10.1080\/21505594.2023.2172264","article-title":"Pathogenicity and virulence of Aspergillus fumigatus","volume":"14","author":"Earle","year":"2023","journal-title":"Virulence"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01382-17","DOI":"10.1128\/AAC.01382-17","article-title":"In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.","volume":"62","author":"Raffetin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: A new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Kontoyiannis","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/IDR.S170952","article-title":"Widespread amphotericin B-resistant strains of Aspergillus fumigatus in Hamilton, Canada","volume":"11","author":"Ashu","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_29","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101310","DOI":"10.1016\/j.mycmed.2022.101310","article-title":"Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species","volume":"32","author":"Fakhim","year":"2022","journal-title":"J. Mycol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"680749","DOI":"10.3389\/fmicb.2021.680749","article-title":"The Elevated Endogenous Reactive Oxygen Species Contribute to the Sensitivity of the Amphotericin B-Resistant Isolate of Aspergillus flavus to Triazoles and Echinocandins","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e0227421","DOI":"10.1128\/aac.02274-21","article-title":"Aspergillus terreus and the Interplay with Amphotericin B: From Resistance to Tolerance?","volume":"66","author":"Dietl","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","unstructured":"(2023, September 22). Available online: https:\/\/www.liofilchem.net\/login.area.mic\/technical_sheets\/MTS40.pdf."},{"key":"ref_35","unstructured":"(2023, September 22). Available online: https:\/\/www.liofilchem.com\/images\/brochure\/mic_test_strip_patent\/MTS06.pdf."},{"key":"ref_36","unstructured":"Guinea, J., Meletiadis, J., Arikan-Akdagli, S., Muehlethaler, K., Kahlmeter, G., Arendrup, M.C., and the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2023, September 20). EUCAST DEFINITIVE DOCUMENT E.DEF 9.4 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Files\/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf."},{"key":"ref_37","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2023, September 20). EUCAST Development Laboratories. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Network_labs\/EDL\/EUCAST_Development_Laboratories.pdf."},{"key":"ref_38","unstructured":"(2023, September 22). Available online: https:\/\/www.liofilchem.net\/login.area.mic\/technical_sheets\/MTS31.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines","volume":"8","author":"Roell","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:20:47Z","timestamp":1760113247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["antibiotics13111005"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13111005","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}